PhoenixBio Co Equity Ratio

What does PhoenixBio Co do? PhoenixBio Co., Ltd., identified by the ticker symbol 6190.T and ISIN JP3803010002, is a specialized entity operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. Headquartered in Higashihiroshima-shi, located in the Hiroshima-Ken prefecture of Japan, the company has established itself as a holding company focused on advanced biotechnological innovations. The firm went public on March 18, 2016, marking a significant milestone in its corporate development and allowing it to access broader capital markets to support its research and development initiatives. Despite its specialized and high-tech nature, PhoenixBio maintains a lean operational structure, currently employing 65 full-time staff members who are dedicated to driving the company's core technological objectives. The primary focus of PhoenixBio lies in the development of proprietary technologies for the mass propagation of human cells into laboratory animals. This niche area of research is critical for the pharmaceutical and biotech industries, as it addresses the limitations of traditional animal models in predicting human drug responses. By creating more physiologically relevant models, the company aims to improve the accuracy and efficiency of preclinical testing. A key component of this effort is the PXB Mouse segment, which is engaged in the sophisticated development of a specific type of mouse model. The PXB Mouse is engineered so that more than 70 percent of its liver tissue is replaced with human hepatocytes. This significant degree of humanization allows the mouse liver to perform metabolic functions much closer to those of a human liver, providing a more accurate platform for drug discovery. The PXB Mouse product is primarily utilized in the preclinical phase of drug discovery, a crucial stage where potential therapeutic compounds are evaluated for safety and efficacy before moving to human clinical trials. By using these humanized mice, pharmaceutical researchers can obtain more reliable data regarding drug metabolism, toxicity, and efficacy, potentially reducing the high failure rates often seen in later stages of clinical development. This technology represents a significant advancement in the field of life sciences tools, offering a bridge between in vitro studies and human clinical applications. As the company continues to refine its mass propagation techniques, it seeks to expand the applicability of its human cell propagation technologies, thereby contributing to the broader goal of improving drug development outcomes. The company’s website, https://phoenixbio.co.jp/, serves as the primary digital hub for stakeholders seeking further information on its ongoing projects and corporate updates. PhoenixBio Co is one of the most popular companies on Eulerpool.